Your browser doesn't support javascript.
Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.
Funk, Tjede; Pharris, Anastasia; Spiteri, Gianfranco; Bundle, Nick; Melidou, Angeliki; Carr, Michael; Gonzalez, Gabriel; Garcia-Leon, Alejandro; Crispie, Fiona; O'Connor, Lois; Murphy, Niamh; Mossong, Joël; Vergison, Anne; Wienecke-Baldacchino, Anke K; Abdelrahman, Tamir; Riccardo, Flavia; Stefanelli, Paola; Di Martino, Angela; Bella, Antonino; Lo Presti, Alessandra; Casaca, Pedro; Moreno, Joana; Borges, Vítor; Isidro, Joana; Ferreira, Rita; Gomes, João Paulo; Dotsenko, Liidia; Suija, Heleene; Epstein, Jevgenia; Sadikova, Olga; Sepp, Hanna; Ikonen, Niina; Savolainen-Kopra, Carita; Blomqvist, Soile; Möttönen, Teemu; Helve, Otto; Gomes-Dias, Joana; Adlhoch, Cornelia.
  • Funk T; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
  • Pharris A; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
  • Spiteri G; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
  • Bundle N; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
  • Melidou A; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
  • Carr M; National Virus Reference Laboratory (NVRL), University College Dublin, Dublin, Ireland.
  • Gonzalez G; International Collaboration Unit, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Garcia-Leon A; National Virus Reference Laboratory (NVRL), University College Dublin, Dublin, Ireland.
  • Crispie F; International Collaboration Unit, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • O'Connor L; Centre for Experimental Pathogen Host Research, University College Dublin, Dublin, Ireland on behalf of the All Ireland Infectious Diseases (AIID) Cohort.
  • Murphy N; Teagasc Food Research Centre, Moorepark, Fermoy, Ireland on behalf of the Irish Coronavirus Sequencing Consortium (ICSC).
  • Mossong J; Health Service Executive - Health Protection Surveillance Centre (HPSC), Dublin, Ireland.
  • Vergison A; Health Service Executive - Health Protection Surveillance Centre (HPSC), Dublin, Ireland.
  • Wienecke-Baldacchino AK; Health Directorate, Findel, Luxembourg.
  • Abdelrahman T; Health Directorate, Findel, Luxembourg.
  • Riccardo F; National Health Laboratory, Dudelange, Luxembourg.
  • Stefanelli P; National Health Laboratory, Dudelange, Luxembourg.
  • Di Martino A; Istituto Superiore di Sanità, Rome, Italy.
  • Bella A; Istituto Superiore di Sanità, Rome, Italy.
  • Lo Presti A; Istituto Superiore di Sanità, Rome, Italy.
  • Casaca P; Istituto Superiore di Sanità, Rome, Italy.
  • Moreno J; Istituto Superiore di Sanità, Rome, Italy.
  • Borges V; Directorate of Analysis and Information, Directorate-General of Health, Lisbon, Portugal.
  • Isidro J; Directorate of Analysis and Information, Directorate-General of Health, Lisbon, Portugal.
  • Ferreira R; Bioinformatics Unit, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
  • Gomes JP; Bioinformatics Unit, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
  • Dotsenko L; Bioinformatics Unit, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
  • Suija H; Bioinformatics Unit, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
  • Epstein J; Health Board, Tallinn, Estonia.
  • Sadikova O; Health Board, Tallinn, Estonia.
  • Sepp H; Health Board, Tallinn, Estonia.
  • Ikonen N; Health Board, Tallinn, Estonia.
  • Savolainen-Kopra C; Health Board, Tallinn, Estonia.
  • Blomqvist S; Finnish Institute for Health and Welfare (THL), Department of Health Security, Helsinki, Finland.
  • Möttönen T; Finnish Institute for Health and Welfare (THL), Department of Health Security, Helsinki, Finland.
  • Helve O; Finnish Institute for Health and Welfare (THL), Department of Health Security, Helsinki, Finland.
  • Gomes-Dias J; Finnish Institute for Health and Welfare (THL), Department of Health Security, Helsinki, Finland.
  • Adlhoch C; Finnish Institute for Health and Welfare (THL), Department of Health Security, Helsinki, Finland.
Euro Surveill ; 26(16)2021 04.
Article in English | MEDLINE | ID: covidwho-1200053
ABSTRACT
We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF 1.7, 95% confidence interval (CI) 1.0-2.9; B.1.351 3.6, 95% CI 2.1-6.2; P.1 2.6, 95% CI 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF 2.3, 95% CI 1.4-3.5; P.1 2.2, 95% CI 1.7-2.8).
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Variants Limits: Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: 1560-7917.ES.2021.26.16.2100348

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Variants Limits: Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: 1560-7917.ES.2021.26.16.2100348